990 related articles for article (PubMed ID: 3346541)
1. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens.
Caspi RR; Roberge FG; Chan CC; Wiggert B; Chader GJ; Rozenszajn LA; Lando Z; Nussenblatt RB
J Immunol; 1988 Mar; 140(5):1490-5. PubMed ID: 3346541
[TBL] [Abstract][Full Text] [Related]
2. Evidence for selective accumulation of V beta 8+ T lymphocytes in experimental autoimmune uveoretinitis induced with two different retinal antigens.
Egwuagu CE; Mahdi RM; Nussenblatt RB; Gery I; Caspi RR
J Immunol; 1993 Aug; 151(3):1627-36. PubMed ID: 8393049
[TBL] [Abstract][Full Text] [Related]
3. Orally induced bystander suppression in experimental autoimmune uveoretinitis occurs only in the periphery and not in the eye.
Wildner G; Thurau SR
Eur J Immunol; 1995 May; 25(5):1292-7. PubMed ID: 7774632
[TBL] [Abstract][Full Text] [Related]
4. Oral tolerance in experimental autoimmune uveoretinitis. Distinct mechanisms of resistance are induced by low dose vs high dose feeding protocols.
Gregerson DS; Obritsch WF; Donoso LA
J Immunol; 1993 Nov; 151(10):5751-61. PubMed ID: 7693817
[TBL] [Abstract][Full Text] [Related]
5. Staphylococcal enterotoxin B is involved in aggravation and recurrence of murine experimental autoimmune uveoretinitis via Vbeta8+CD4+ T cells.
Kohno H; Sakai T; Tsuneoka H; Imanishi K; Saito S
Exp Eye Res; 2009 Oct; 89(4):486-93. PubMed ID: 19523946
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming.
Sartani G; Silver PB; Rizzo LV; Chan CC; Wiggert B; Mastorakos G; Caspi RR
Invest Ophthalmol Vis Sci; 1996 Oct; 37(11):2211-8. PubMed ID: 8843907
[TBL] [Abstract][Full Text] [Related]
7. Rodent models of experimental autoimmune uveitis.
Agarwal RK; Caspi RR
Methods Mol Med; 2004; 102():395-419. PubMed ID: 15286397
[TBL] [Abstract][Full Text] [Related]
8. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype.
Avichezer D; Silver PB; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):127-31. PubMed ID: 10634611
[TBL] [Abstract][Full Text] [Related]
9. Genetic control of susceptibility to experimental autoimmune uveoretinitis in the mouse model. Concomitant regulation by MHC and non-MHC genes.
Caspi RR; Grubbs BG; Chan CC; Chader GJ; Wiggert B
J Immunol; 1992 Apr; 148(8):2384-9. PubMed ID: 1560198
[TBL] [Abstract][Full Text] [Related]
10. Thymic expression of autoantigens correlates with resistance to autoimmune disease.
Egwuagu CE; Charukamnoetkanok P; Gery I
J Immunol; 1997 Oct; 159(7):3109-12. PubMed ID: 9317106
[TBL] [Abstract][Full Text] [Related]
11. Amelioration of experimental autoimmune uveoretinitis (EAU) with an inhibitor of nuclear factor-kappaB (NF-kappaB), pyrrolidine dithiocarbamate.
Kitamei H; Iwabuchi K; Namba K; Yoshida K; Yanagawa Y; Kitaichi N; Kitamura M; Ohno S; Onoé K
J Leukoc Biol; 2006 Jun; 79(6):1193-201. PubMed ID: 16574770
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
13. Exogenous nitric oxide inhibits experimental autoimmune uveoretinitis development in Lewis rats by modulation of the Th1-dependent immune response.
Kwak HJ; Yang YS; Pae HO; Kim YM; Chung HT
Mol Cells; 2001 Oct; 12(2):178-84. PubMed ID: 11710518
[TBL] [Abstract][Full Text] [Related]
14. IL-18 not required for IRBP peptide-induced EAU: studies in gene-deficient mice.
Jiang HR; Wei X; Niedbala W; Lumsden L; Liew FY; Forrester JV
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):177-82. PubMed ID: 11133864
[TBL] [Abstract][Full Text] [Related]
15. Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice.
Caspi RR; Chan CC; Grubbs BG; Silver PB; Wiggert B; Parsa CF; Bahmanyar S; Billiau A; Heremans H
J Immunol; 1994 Jan; 152(2):890-9. PubMed ID: 8283058
[TBL] [Abstract][Full Text] [Related]
16. The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment.
Silver PB; Chan CC; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Nov; 40(12):2898-905. PubMed ID: 10549650
[TBL] [Abstract][Full Text] [Related]
17. Effects of experimental ocular inflammation on ocular immune privilege.
Ohta K; Wiggert B; Taylor AW; Streilein JW
Invest Ophthalmol Vis Sci; 1999 Aug; 40(9):2010-8. PubMed ID: 10440255
[TBL] [Abstract][Full Text] [Related]
18. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
[TBL] [Abstract][Full Text] [Related]
19. Mapping immune responses to mRBP-3 1-16 peptide with altered peptide ligands.
Guyver CJ; Copland DA; Calder CJ; Sette A; Sidney J; Dick AD; Nicholson LB
Invest Ophthalmol Vis Sci; 2006 May; 47(5):2027-35. PubMed ID: 16639012
[TBL] [Abstract][Full Text] [Related]
20. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.
Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
